Granulocyte-macrophage colony-stimulating factor protects mice against hepatocellular carcinoma by ameliorating intestinal dysbiosis and attenuating inflammation

被引:12
作者
Wu, Yong-Na [1 ,2 ,3 ,4 ,5 ]
Zhang, Lei [4 ,5 ]
Chen, Tuo [1 ,2 ,3 ]
Li, Xun [4 ,5 ]
He, Li-Hong [4 ]
Liu, Guang-Xiu [1 ,2 ,3 ]
机构
[1] Chinese Acad Sci, Northwest Inst Ecoenvironm & Resources, Key Lab Desert & Desertificat, Lanzhou 730000, Gansu, Peoples R China
[2] Key Lab Extreme Environm Microbial Resources & En, Lanzhou 730000, Gansu, Peoples R China
[3] Univ Chinese Acad Sci, Beijing 100049, Peoples R China
[4] Lanzhou Univ, Hosp 1, Lanzhou 730000, Gansu, Peoples R China
[5] Key Lab Biol Therapy & Regenerat Med Transformat, Lanzhou 730000, Gansu, Peoples R China
基金
中国国家自然科学基金;
关键词
Granulocyte-macrophage colony-stimulating factor; Microbiome; Inflammation; Hepatocellular carcinoma; GUT MICROBIOTA; NONALCOHOLIC STEATOHEPATITIS; RECEPTOR; 4; GM-CSF; CELLS; SUCCINATE; METABOLITES; DEFICIENCY; MECHANISMS; BARRIER;
D O I
10.3748/wjg.v26.i36.5420
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide. The gut microbiota can help maintain healthy metabolism and immunity. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a critical factor in promoting health and homeostasis; it promotes intestinal immunity, stimulates bone marrow precursors to generate macrophage colonies, and enhances the antibacterial and antitumor activity of circulating monocytes. As such, GM-CSF may protect against HCC development by regulating immunity as well as intestinal microecology. AIM To investigate the impact of GM-CSF on the gut microbiome and metabolic characteristics of HCC. METHODS Thirty-six male BALB/c nude mice were divided into three groups: Control (n= 10), HCC (n= 13), and HCC + GM-CSF (GM-CSF overexpression,n= 13). We utilized HCC cells to establish orthotopic transplantation tumor models of HCC with normal and over-expressing GM-CSF. Liver injury, immune inflammatory function and intestinal barrier function were evaluated. The fecal microbiome and metabolome were studied using 16S rRNA absolute quantification sequencing and gas chromatography-mass spectrometry. RESULTS GM-CSF overexpression significantly affected the gut microbiome of mice with HCC and resulted in a high abundance of organisms of the generaRoseburia,BlautiaandButyricimonass, along with a significant reduction inPrevotella,Parabacteroides,Anaerotruncus,Streptococcus,Clostridium, andMucispirillum. Likewise, GM-CSF overexpression resulted in a substantial increase in fecal biotin and oleic acid levels, along with a prominent decrease in the fecal succinic acid, adenosine, fumaric acid, lipoic acid, and maleic acid levels. Correlation analysis revealed that the intestinal microbiota and fecal metabolites induced by GM-CSF were primarily involved in pathways related to reducing the inflammatory response, biotin metabolism, and intestinal barrier dysfunction. CONCLUSION GM-CSF can protect against HCC development by regulating immunity and modulating the abundance of specific intestinal microorganisms and their metabolites. This study provides new insights into the therapeutic approaches for HCC.
引用
收藏
页码:5420 / 5436
页数:18
相关论文
共 50 条
  • [21] SPECIFIC HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR ANTAGONISTS
    HERCUS, TR
    BAGLEY, CJ
    CAMBARERI, B
    DOTTORE, M
    WOODCOCK, JM
    VADAS, MA
    SHANNON, MF
    LOPEZ, AF
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (13) : 5838 - 5842
  • [22] CDNA CLONING OF PORCINE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
    INUMARU, S
    TAKAMATSU, H
    IMMUNOLOGY AND CELL BIOLOGY, 1995, 73 (05) : 474 - 476
  • [23] GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN ACUTE NONLYMPHOCYTIC LEUKEMIA
    FANIN, R
    BACCARANI, M
    JOURNAL OF INTERNAL MEDICINE, 1994, 236 (05) : 487 - 493
  • [24] Emerging paradigms in granulocyte-macrophage colony-stimulating factor signaling
    GomezCambronero, J
    Veatch, C
    LIFE SCIENCES, 1996, 59 (25-26) : 2099 - 2111
  • [25] New clinical applications of granulocyte-macrophage colony-stimulating factor
    Masucci, G
    MEDICAL ONCOLOGY, 1996, 13 (03): : 149 - 154
  • [26] Crystal structure of the Fab region of a neutralizing antibody against granulocyte-macrophage colony-stimulating factor
    Angkawidjaja, Clement
    Torashima, Takashi
    ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS, 2019, 75 : 634 - 639
  • [27] Central inhibition of granulocyte-macrophage colony-stimulating factor is analgesic in experimental neuropathic pain
    Nicol, Louise S. C.
    Thornton, Peter
    Hatcher, Jon P.
    Glover, Colin P.
    Webster, Carl I.
    Burrell, Matthew
    Hammett, Kessia
    Jones, Clare A.
    Sleeman, Matthew A.
    Billinton, Andrew
    Chessell, Iain
    PAIN, 2018, 159 (03) : 550 - 559
  • [28] Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on glial scar formation after spinal cord injury in rats
    Chung, Joonho
    Kim, Moon Hang
    Yoon, Yong Je
    Kim, Kil Hwan
    Park, So Ra
    Choi, Byung Hyune
    JOURNAL OF NEUROSURGERY-SPINE, 2014, 21 (06) : 966 - 973
  • [29] Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy
    Wong, SF
    Chan, HO
    PHARMACOTHERAPY, 2005, 25 (03): : 372 - 378
  • [30] NMR assignment of human granulocyte-macrophage colony-stimulating factor
    Sauve, Simon
    Gingras, Genevieve
    Aubin, Yves
    BIOMOLECULAR NMR ASSIGNMENTS, 2008, 2 (01) : 5 - 7